Suche starten De menü de ClientConnect
Suche starten
Top-5-Suchergebnisse Alle Ergebnisse anzeigen Erweiterte Suche
Häufigste Suchbegriffe
Meistbesuchte Seiten
    Referenz: 20210328
    Veröffentlichungsdatum: 9 Februar 2023

    Projektträger – zwischengeschaltetes Finanzinstitut




    The project will finance the promoter's research, development and innovation (RDI) investments to develop a pipeline of proprietary gene therapy candidates.

    Additionality and Impact

    The project concerns an operation under the European Growth Finance Facility. The purpose of the loan is to provide direct, equity-type financing under EIB's Venture Debt Instrument to support Research, Development and Innovation ("RDI") activities of the innovative company 'Gensight', an SME based in France. The financing of this project addresses the failure in financial markets for RDI, arising from limited access to commensurate financing as a result of factors such as information asymmetries, misalignment of incentives, etc. Gensight is a clinical-stage biopharmaceutical company focused on the development of gene therapies with the potential to provide patients with a long-lasting cure for severe genetic blinding retinal diseases. If successful, the project will have a high socio-economic impact. In addition, by creating knowledge externalities, the project will provide significant socio-economic benefits, will strengthen France and Europe's leading position in biotechnologies, and it will help to retain skilled staff engaged in the Company's RDI activities.


    The company is developing a pipeline of proprietary gene therapy candidates to provide patients with a long-lasting cure for severe genetic blinding retinal diseases, for which there are currently no approved treatments.


    • Industrie - Verarbeitendes Gewerbe/Herstellung von Waren

    Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)

    EUR 35 million

    Gesamtkosten (voraussichtlicher Betrag)

    EUR 90 million


    The related RDI investments are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during appraisal.


    The promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the project procurement procedures are expected to be in line with EIB guidelines for private sector projects. The EIB will verify details during the project due diligence.


    Unterzeichnet - 3/11/2022

    In Prüfung
    25 August 2022
    3 November 2022


    Bis Finanzierungen vom Verwaltungsrat genehmigt und anschließend unterzeichnet werden, befinden sich die Projekte in der Prüfungs- oder Verhandlungsphase. Die Angaben auf dieser Seite sind daher unverbindlich.
    Sie dienen lediglich der Transparenz und stellen nicht die offizielle EIB-Politik dar (vgl. auch die erklärenden Anmerkungen).


    Frankreich Industrie